Rho Seoung Yoon, Hwang Ho Kyoung, Chong Jae Uk, Yoon Dong Sup, Lee Woo Jung, Kang Chang Moo
Division of Hepatobiliary and Pancreas, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Pancreaticobiliary Cancer Clinic, Institute of Gastroenterology, Yonsei University Health System, Seoul, Korea.
ANZ J Surg. 2019 May;89(5):503-508. doi: 10.1111/ans.15030. Epub 2019 Mar 5.
Immunologic factors such as neutrophil-lymphocyte ratio and platelet-lymphocyte ratio play an important role in predicting the oncologic outcome of patients in pancreatic ductal adenocarcinoma (PDAC). It is hypothesized that host immunity represented by total lymphocyte count at diagnostic stage would influence oncologic outcome in left-sided PDAC.
Between January 1992 and August 2017, total of 112 patients who underwent distal pancreatectomy for left-sided PDAC were included and analysed.
At the time of the diagnosis, total lymphocyte count at diagnosis of left-sided PDAC was 1.8 ± 0.7 10 /μL (mean value ± standard deviation). Among different cut-off values, 1.7 showed most powerful significant differences in long-term oncologic outcomes. The patients with preoperative lymphocyte count (≤1.7) was associated with early recurrence (median 8.4 months versus 18.1 months, P = 0.011) and shorter survival (median 18.6 months versus 35.9 months, P = 0.028). Patients with preoperative total lymphocyte count over 1.7 showed higher white blood cell count (P < 0.001), platelet count (P = 0.039), neutrophil count (P = 0.004) and monocyte count (P = 0.001). However, more interestingly, neutrophil-lymphocyte ratio (P < 0.001) and platelet-lymphocyte ratio (P < 0.001) were found to be significantly higher in those with total lymphocyte count less than 1.7. Lymphocyte to monocyte ratio was inversely related to preoperative total lymphocyte count (P < 0.001). Only age was identified to be significantly different (P = 0.007). However, other clinicopathological parameters generally known to be related to tumour aggressiveness, were not different between two groups.
In conclusion, preoperative total lymphocyte at diagnostic stage is simple, and good prognostic factor in left-sided pancreatic cancer.
中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值等免疫因素在预测胰腺导管腺癌(PDAC)患者的肿瘤学结局中发挥着重要作用。据推测,诊断阶段的总淋巴细胞计数所代表的宿主免疫会影响左侧PDAC的肿瘤学结局。
纳入并分析了1992年1月至2017年8月期间因左侧PDAC接受胰体尾切除术的112例患者。
在诊断时,左侧PDAC诊断时的总淋巴细胞计数为1.8±0.7×10⁹/μL(平均值±标准差)。在不同的临界值中,1.7在长期肿瘤学结局方面显示出最显著的差异。术前淋巴细胞计数≤1.7的患者与早期复发相关(中位数8.4个月对18.1个月,P = 0.011),且生存期较短(中位数18.6个月对35.9个月,P = 0.028)。术前总淋巴细胞计数超过1.7的患者白细胞计数(P < 0.001)、血小板计数(P = 0.039)、中性粒细胞计数(P = 0.00)和单核细胞计数(P = 0.001)较高。然而,更有趣的是,总淋巴细胞计数低于1.7的患者中性粒细胞与淋巴细胞比值(P < 0.001)和血小板与淋巴细胞比值(P < 0.001)显著更高。淋巴细胞与单核细胞比值与术前总淋巴细胞计数呈负相关(P < 0.001)。仅年龄被确定有显著差异(P = 0.007)。然而,两组之间通常已知与肿瘤侵袭性相关的其他临床病理参数并无差异。
总之,诊断阶段的术前总淋巴细胞是左侧胰腺癌简单且良好的预后因素。